ライフサイエンスコーパス: vaccine recipient

1 , urine, or saliva samples obtained from any vaccine recipient.

2 and antibody responses were detected in all vaccine recipients.

3 it should be translated into adulthood among vaccine recipients.

4 related to sexual activity among adolescent vaccine recipients.

5 or adverse reproductive health effects among vaccine recipients.

6 of 75-microg vaccine, and 77% of 135-microg vaccine recipients.

7 of 75-microg vaccine, and 92% of 135-microg vaccine recipients.

8 l, and antibody responses in the majority of vaccine recipients.

9 jected 1 intussusception event/38,000-59,000 vaccine recipients.

10 pneumococcal disease within populations and vaccine recipients.

11 growth in cell cultures and the organisms of vaccine recipients.

12 cinia virus from vaccination sites of Dryvax vaccine recipients.

13 ty was unchanged for about half of the adult vaccine recipients.

14 A single dose was immunogenic in almost all vaccine recipients.

15 nd D antigens in a significant proportion of vaccine recipients.

16 rs and causes reactogenicity in up to 30% of vaccine recipients.

17 r mild diarrhea occurred in six (22%) of the vaccine recipients.

18 rative responses (LPRs) developed in <30% of vaccine recipients.

19 lative resistance to HIV-1 as well as in HIV vaccine recipients.

20 ects reduce the risk of reactive diarrhea in vaccine recipients.

21 equency of arthritis or neurologic events in vaccine recipients.

22 safety for laboratory workers and potential vaccine recipients.

23 id not differ significantly between ID vs IM vaccine recipients.

24 ry low rate, they can cause poliomyelitis in vaccine recipients.

25 responses against gp120 were induced in all vaccine recipients.

26 ific Tfh cells were increased in RV144 trial vaccine recipients.

27 The LTPS enrolled 6867 SPS vaccine recipients.

28 e increased rate of HIV-1 infections seen in vaccine recipients.

29 and unexpected excess HIV infections in the vaccine recipients.

30 ere within the range observed in human RTS,S vaccine recipients.

31 iating nonclonally related antibodies from 6 vaccine recipients.

32 erum antibody levels) was detected in 70% of vaccine recipients.

33 an HIV-1 RNA level over time was lower among vaccine recipients.

34 iclovir treatment (p=0.0287) were reduced in vaccine recipients.

35 5; 95% CI, 0.24-0.51) were less likely among vaccine recipients.

36 trations persisted in > or =85% of conjugate-vaccine recipients 104 weeks later.

37 Of 39 vaccine recipients, 13 were protected and 26 were not.

38 vaccine recipients, 17 HIV-1-infected rgp120 vaccine recipients, 15 HIV-1-infected placebo recipients

39 edian follow-up of 42 months (IQR 31-42), 63 vaccine recipients (16%) had HIV-1 infection compared wi

40 eumoniae density was substantially higher in vaccine recipients (16,687 vs. 1935 gene copies per mill

41 te vaccine recipients than in polysaccharide vaccine recipients (16.66 microg/mL vs. 8.31 microgm/mL;

42 e were evaluated in 19 HIV-1-infected rgp160 vaccine recipients, 17 HIV-1-infected rgp120 vaccine rec

43 either the primary end points (22/3528 V710 vaccine recipients [2.6 per 100 person-years] vs 27/3517

44 Twenty-three placebo recipients (49%) and 16 vaccine recipients (29%) reported respiratory symptoms (

45 e first 14 days after vaccination (1219/3958 vaccine recipients [30.8%; 95% CI, 29.4%-32.3%] and 866/

46 e significantly less frequent in bivalent ca vaccine recipients (31%) than in monovalent ca H1N1 reci

47 iters were significantly higher in conjugate vaccine recipients (755.6 vs 37.6 for group A, P<.001; 3

48 nation, 93% (n=139/149) to 100% (n=48/48) of vaccine recipients achieved protective hSBA titres equal

49 Follow-up of vaccine recipients acquiring HSV-2 infection showed vacc

50 Transient rVSV viremia was noted in all the vaccine recipients after dose 1.

51 nism explaining the excess HIV infections in vaccine recipients after rAd5-HIV vaccination and highli

52 sions in high-dose compared to standard-dose vaccine recipients, an outcome not shown in randomised s

53 e were compared over 692,819 person-years in vaccine recipients and 1,534,280 person-years in vaccine

54 After inoculation, 255 (1.4%) vaccine recipients and 254 (1.4%) placebo recipients rep

55 isation showed no difference between the 287 vaccine recipients and 281 placebo recipients in rate of

56 ited reports of grade 3 symptoms in 17.0% of vaccine recipients and 3.2% of placebo recipients.

57 ite side effects were reported by 1604 (48%) vaccine recipients and 539 (16%) placebo recipients in t

58 confirmed cases of herpes zoster (315 among vaccine recipients and 642 among placebo recipients) and

59 e second year, after the third injection, 16 vaccine recipients and 66 placebo recipients contracted

60 07 cases of postherpetic neuralgia (27 among vaccine recipients and 80 among placebo recipients) were

61 ained, over an 18-month period, from 101 ACP-vaccine recipients and 99 control subjects, to assess AC

62 There was no significant difference between vaccine recipients and control groups in incidence of HI

63 s were available for 109 of the seronegative vaccine recipients and for 110 of the seronegative place

64 tent but risk causing adenovirus diseases in vaccine recipients and health care workers.

65 analyzed cytokine responses in both primary vaccine recipients and revaccinated subjects every other

66 pA ELISA to assess the antibody responses of vaccine recipients and subjects with Lyme disease.

67 tude and duration of the boost in VZV-CMI in vaccine recipients and the relationship of this boost to

68 in placebo recipients (compared with zoster vaccine recipients) and in older individuals.

69 Env responses predominated (19 of 30; 63% of vaccine recipients) and were mediated by polyfunctional

70 Haemophilus influenza meningitis (1% rabies-vaccine recipients), and one case of tuberculosis (1% RT

71 hL3, which produced acute febrile illness in vaccine recipients, and DENV-2 PDK53, which has a good c

72 rum samples from HIV-infected donors, VAX004 vaccine recipients, and healthy HIV-negative subjects us

73 m samples from 80%-90% of bivalent conjugate vaccine recipients, and these responses were similar to

74 reased HIV-1 infection rates in subgroups of vaccine recipients are being explored.

75 ve examined serum cytokine levels in primary vaccine recipients at 1 and 3-5 weeks after vaccination

76 uantification were shown in 37% (n=18/49) of vaccine recipients at 6 months, in 29% (n=14/48) at 12 m

77 V antibodies were significantly increased in vaccine recipients at 6 weeks after vaccination.

78 4 months of age was investigated by boosting vaccine recipients at age 13-16 months or 4 years with 1

79 5 antibody titre 200 or less, 24 (3%) of 741 vaccine recipients became HIV-1 infected versus 21 (3%)

80 titate 108 serum cytokines and chemokines in vaccine recipients before and 1 week after primary immun

81 The potential for vaccine recipients being misclassified as HIV infected i

82 ), 90% of placebo and 87% of live attenuated vaccine recipients but only 23% of inactivated vaccine r

83 the injection site were more frequent among vaccine recipients but were generally mild.

84 an immunodeficiency virus (HIV) type 1 gp120 vaccine recipients by age, sex, and race.

85 a virus-infected patients and from influenza vaccine recipients by complement-dependent lysis (CDL) a

86 dy responses were detected in 15 (50%) of 30 vaccine recipients by enzyme-linked immunosorbant assay

87 ytokine staining assay and in 22 (73%) of 30 vaccine recipients by enzyme-linked immunospot assay.

88 immunosorbant assay and in 28 (93.3%) of 30 vaccine recipients by immunoprecipitation followed by We

89 ence, the time period over which an infected vaccine recipient can transmit to susceptible sex partne

90 iting, diarrhea, or behavioral changes among vaccine recipients, compared with placebo recipients, du

91 and duration of symptoms observed in primary vaccine recipients, compared with revaccinated subjects,

92 vaccine trial, was 22-fold higher in Chiron vaccine recipients, compared with RV144 vaccinees.

93 HIV-specific T cell lines obtained from vaccine recipients confirmed V2 specificity, polyfunctio

94 ccine recipients but only 23% of inactivated vaccine recipients demonstrated serologic confirmation o

95 he pathogen Borrelia burgdorferi, and 95% of vaccine recipients develop substantial titers of antibod

96 tive placebo recipients; 84% of seronegative vaccine recipients developed a > or =4-fold increase in

97 Vaccine recipients developed lymphoproliferative respons

98 logic category, at least 79% of HIV-infected vaccine recipients developed VZV-specific antibody and/o

99 ients and four (4.0%, 1.1-9.8) of 101 rabies-vaccine recipients died, but no deaths were deemed relat

100 ite a trend favoring viral suppression among vaccine recipients, differences in HIV-1 RNA levels did

101 when it is administered alone, up to 14% of vaccine recipients do not achieve protective levels of a

102 atal animals were not considered as suitable vaccine recipients either because of immune immaturity o

103 Eleven vaccine recipients exhibited delayed onset of parasitemi

104 As a group, vaccine recipients experienced more injection-site react

105 monia (1% RTS,S/AS01 recipients vs 3% rabies-vaccine recipients), five cases of gastroenteritis (3% R

106 ritis (3% RTS,S/AS01 recipients vs 2% rabies-vaccine recipients), five cases of malnutrition (2% RTS,

107 en to further assess vaccine efficacy in SPS vaccine recipients followed for up to 11 years postvacci

108 re detected in 28 (93.3%) and 18 (60%) of 30 vaccine recipients for CD4(+) and CD8(+) T cells, respec

109 3 HI titers, and that bPIV3 vaccine prevents vaccine recipients from developing antibody profiles of

110 In infants of GBS vaccine recipients, GBS serotype-specific antibody geome

111 Twenty percent of vaccine recipients generated detectable cytolytic respon

112 Following seroconversion to CHIKV, CHIKV vaccine recipients' geometric mean titers (GMTs) to VEEV

113 Protected vaccine recipients had a higher CSP-specific IgG titer (

114 ter 3 doses of vaccine was.84; however, more vaccine recipients had an elevated ELISA titer paired wi

115 ients and 12 (11.9%, 6.3-19.8) of 101 rabies-vaccine recipients had at least one serious adverse even

116 Chiron vaccine recipients had higher and more-durable IgG respo

117 In total, 16, 19, and 15 vaccine recipients had increases after 1, 2, and 3 doses

118 Ten placebo recipients but no vaccine recipients had laboratory-confirmed symptomatic

119 Primary vaccine recipients had maximal levels of granulocyte-col

120 All vaccine recipients had positive HPV-11 VLP-specific lymp

121 By day 28, all the vaccine recipients had seroconversion as assessed by an

122 By day 57, 52 (92%) of vaccine recipients had seroconverted (microneutralisatio

123 ntrol subjects and 3 (1.7%) of 180 influenza vaccine recipients had serologic evidence of influenza t

124 All vaccine recipients had specific IgG detectable 21 days p

125 ty complex class I allelic expression by the vaccine recipient in determining the relative breadth of

126 At rechallenge, 4 of 9 vaccine recipients in each group were still completely p

127 os are higher in infected than in uninfected vaccine recipients in RV144.

128 y of Fc-mediated Ab effector responses among vaccine recipients in the VAX004 trial and in HIV-infect

129 ial revealed increased mortality rates among vaccine recipients in whom postsurgical S. aureus infect

130 in 75% (267) of the 25% random sample of all vaccine recipients (including both low and high Ad5 anti

131 y strong and were present in the majority of vaccine recipients, including a strong response against

132 h of HIV-specific CD8(+) T cell responses in vaccine recipients, independent of type-specific preexis

133 The increased risk of HIV-1 acquisition in vaccine recipients, irrespective of number of doses rece

134 ion is leaky (ie, the susceptibility of each vaccine recipient is reduced by a factor that is equal t

135 The induction of VISP in HIV vaccine recipients is common, especially with vaccines c

136 how this affects the antibody repertoire of vaccine recipients is inadequate.

137 mmunodominance in uninfected, HLA-A*0201 HIV vaccine recipients is similar to that seen in chronicall

138 oliovirus vaccine (OPV) in the intestines of vaccine recipients leads to reversions that increase vir

139 -tFliC MNP boosting immunization to seasonal vaccine recipients may be a rapid approach for increasin

140 e slightly higher rates of hepatitis A among vaccine recipients may indicate a true modest difference

141 Increased rates of pneumococcal disease in vaccine recipients may necessitate a reappraisal of this

142 onses solely from blood mononuclear cells of vaccine recipients may not suffice to compare the potenc

143 th vaccine formulation and dietary status of vaccine recipients may significantly affect the efficacy

144 jected 1 intussusception event/11,000-16,000 vaccine recipients; modeling of a 2-dose schedule beginn

145 Most vaccine recipients mounted potent neutralizing antibody

146 In 2 settings, 0.5% and 3.0% of vaccine recipients needed short-term sick leave.

147 nosorbent assay (ELISA) antibody and, for gB-vaccine recipients, neutralizing antibody.

148 Among vaccine recipients, no important reduction in the number

149 was 44% (95% CI 31-55); all but one case in vaccine recipients occurred in women infected with HPV16

150 Among 34 HIV vaccine recipients of live canarypox vector expressing m

151 e recipients), one case of sepsis (1% rabies-vaccine recipients), one case of Haemophilus influenza m

152 ition (2% RTS,S/AS01 recipients vs 3% rabies-vaccine recipients), one case of sepsis (1% rabies-vacci

153 V-1 infection risk in the CT- or TT-carrying vaccine recipients only.

154 r and more-durable IgG responses than VaxGen vaccine recipients or ALVAC/AIDSVAX vaccinees, with vacc

155 ack Ag-specific plasmablast responses in HIV-vaccine recipients over a period of 42 d and performed a

156 ring in 69% of placebo recipients vs. 37% of vaccine recipients, P=0.006) and Norwalk virus infection

157 ection (82% of placebo recipients vs. 61% of vaccine recipients, P=0.05).

158 Lower mucosal VL was observed among vaccine recipients, primarily in semen (P = .04).

159 ction is all-or-nothing (ie, a proportion of vaccine recipients receive complete protection [VE] and

160 Vaccine recipients received 3 intramuscular injections o

161 ing and not receiving HAART, and second-time vaccine recipients receiving HAART.

162 ents and 37 (36.6%, 27.3-46.8) of 101 rabies-vaccine recipients (relative risk 1.1, 95% CI 0.8-1.6).

163 Overall, 48.5% and 30.9% of RSV vaccine recipients reported local and systemic solicited

164 A total of 977 (56.6%) of the vaccine recipients reporting local side effects were age

165 19 (48%) of 40 vaccine recipients required cytomegalovirus-specific ant

166 4.2 per 100 patient-years in the placebo and vaccine recipients, respectively (P =.58).

167 clade B strains were seen in 10% and 15% of vaccine recipients, respectively, but responses against

168 Human vaccine recipients responded to the peptide sequences id

169 ere compared with vaccine-induced responses, vaccine recipient responses were > or =1 log lower, whic

170 systemic CD8(+) CTL clones established in 1 vaccine recipient revealed similar Env-specific response

171 apid tests, and Western blots) and result in vaccine recipients' serum being identified as reactive a

172 Canarypox or vaccinia vaccine recipients' serum with or without HIV envelope g

173 increase in stool rotavirus IgA, whereas 31 vaccine recipients showed an increase after at least 1 d

174 groups, at 7 days postboost, at least 86% of vaccine recipients showed Ebola-specific T-cell response

175 rmed detailed assessment of an HIV-1 gag DNA vaccine recipient (subject 00015) who was previously uni

176 ence of infection with ALV-E or EAV in 43 YF vaccine recipients suggests low risks for transmission o

177 Vaccine recipients tended to have broader, more robust,

178 Cellular responses were observed in 57% of vaccine recipients tested and were CD4 predominant.

179 s to the vaccine sequence for sequences from vaccine recipients than from placebo recipients.

180 occus were significantly higher in conjugate vaccine recipients than in polysaccharide vaccine recipi

181 bodies were of low avidity, whereas in H-DNA vaccine recipients, the antibodies were of high avidity.

182 btained in an observer-blind manner, and the vaccine recipient, their parent or carer, the funder, an

183 le the antibody (Ab) repertoire of protected vaccine recipients, using recombinant phages encoding ra

184 ough infections occur in partially protected vaccine recipients, vaccination likely contributes to ea

185 18 of 107 placebo recipients and two of 108 vaccine recipients (vaccine efficacy 89.0% [95% CI 65.4-

186 ter inoculation, herpes zoster occurred in 7 vaccine recipients versus 24 placebo recipients.

187 ised dropout rate (7.7% [95% CI 6.2-9.5] for vaccine recipients vs 8.8% [7.1-10.7] for placebo recipi

188 1 of 10 study sites, from 37 placebo and 37 vaccine recipients was measured.

189 double-blind study of 162 HIV-negative RV144 vaccine recipients, we evaluated 2 additional boosts, gi

190 n of a rich set of data collected from RV144 vaccine recipients, we here employ machine learning meth

191 Only 17% of the vaccine recipients were able to generate an increase in

192 The viral burdens in the infected rgp120 vaccine recipients were also determined, and they were f

193 Serum antibodies from these human vaccine recipients were also found to be preferentially

194 Thirty-nine vaccine recipients were assessed at study entry; on the

195 ation (day 26-30) serum specimens from 80 VV vaccine recipients were examined for immunoglobulin G an

196 d not receive a booster dose; 67 of 75 study vaccine recipients were followed up at 8 months.

197 Vaccine recipients were more likely than placebo recipie

198 Herpes zoster vaccine recipients were more likely to be white, women,

199 Vaccine recipients were more likely to experience runny

200 Protected vaccine recipients were rechallenged 5 months later.

201 Serum samples from 30 vaccine recipients were selected based upon relative enz

202 Primary vaccine recipients were significantly more likely to hav

203 Primary vaccine recipients were significantly more likely to hav

204 Vaccine recipients were stratified by sex, race, and hig

205 ks of transmission, serum samples from 43 YF vaccine recipients were studied.

206 Overall, 490 serum specimens from 461 vaccine recipients were tested; 100 (20.4%) reacted on a

207 There was one death in a GBS-vaccine recipient, which too was unrelated to vaccinatio

208 of 75-microg vaccine, and 67% of 135-microg vaccine recipients, while responses to B were seen in 4%

209 OspA-vaccine recipients who acquired Lyme disease had signifi

210 Scarification and intradermal vaccine recipients who developed cutaneous pox lesions h

211 lted in increased morbidity and mortality in vaccine recipients who subsequently contracted RSV.

212 rase chain reaction and sequence analysis in vaccine recipients who tested positive for anti-HBc and/

213 versely correlated with risk of infection in vaccine recipients with low IgA; therefore, we hypothesi

214 omic variation among specimens obtained from vaccine recipients with postvaccination rash or herpes z

215 Secondary transmission of Oka VZV from vaccine recipients with postvaccination vesicular rashes

216 ethal complication that develops in smallpox vaccine recipients with severely impaired cellular immun